Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM4 | O15151 | 3/20 | 0.54 |
| ▸ | TP53 | P04637 | 3/20 | 0.54 |
| ▸ | CASP3 | P42574 | 3/20 | 0.52 |
| ▸ | MDM2 | Q00987 | 5/20 | 0.49 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | SLC17A5 | Q9NRA2 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL120671 | 1.00 | MDM4 (0.54) | MDM4TP53CASP3MDM2PIN1 | |
| SCHEMBL2308310 | 1.00 | MDM4 (0.54) | MDM4TP53CASP3MDM2PIN1 | |
| SCHEMBL2308312 | 1.00 | MDM4 (0.54) | MDM4TP53CASP3MDM2PIN1 | |
| SCHEMBL9186701 | 0.92 | MDM4 (0.59) | MDM4TP53CASP3MDM2KMT2A | |
| SCHEMBL8653785 | 0.92 | MDM4 (0.59) | MDM4TP53CASP3MDM2KMT2A | |
| SCHEMBL8653790 | 0.92 | MDM4 (0.59) | MDM4TP53CASP3MDM2KMT2A | |
| SCHEMBL8654704 | 0.92 | MDM4 (0.59) | MDM4TP53CASP3MDM2KMT2A | |
| SCHEMBL16744152 | 0.87 | CASP3 (0.55) | MDM4TP53CASP3MDM2KMT2A | |
| SCHEMBL8227090 | 0.87 | CASP3 (0.55) | MDM4TP53CASP3MDM2KMT2A | |
| SCHEMBL8234371 | 0.87 | CASP3 (0.55) | MDM4TP53CASP3MDM2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8338565-B2 | Macrocyclic compounds for inhibition of tumor necrosis factor alpha | ENSEMBLE THERAPEUTICS CORPORATION (US) | 2012-12-25 | — | — | US | disclosed |
| EP-2350031-A2 | MACROCYCLIC COMPOUNDS FOR INHIBITION OF TUMOR NECROSIS FACTOR ALPHA | Ensemble Therapeutics Corporation (US) | 2011-08-03 | — | — | EP | disclosed |
| US-20100152099-A1 | MACROCYCLIC COMPOUNDS FOR INHIBITION OF TUMOR NECROSIS FACTOR ALPHA | ENSEMBLE THERAPEUTICS CORPORATION | 2010-06-17 | — | — | US | disclosed |
| WO-2010022249-A2 | MACROCYCLIC COMPOUNDS FOR INHIBITION OF TUMOR NECROSIS FACTOR ALPHA | ENSEMBLE DISCOVERY CORPORATION (US) | 2010-02-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100152099-A1 | MACROCYCLIC COMPOUNDS FOR INHIBITION OF TUMOR NECROSIS FACTOR ALPHA | TNF, CD40, TNFRSF1A | MDM4 1060/4885TP53 573/4885CASP3 549/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.